Article
Clinical Neurology
Jean-Pierre Bellier, Yuqi Cai, Sarah M. Alam, Thorsten Wiederhold, Arica Aiello, Jonathan S. Vogelgsang, Sabina Berretta, Jasmeer P. Chhatwal, Dennis J. Selkoe, Lei Liu
Summary: A wide array of post-translational modifications of the tau protein occurs in Alzheimer's disease (AD) and they are critical to pathogenesis and biomarker development. Several promising tau markers, pT181, pT217, and pT231, rely on increased phosphorylation within a common molecular motif threonine-proline-proline (TPP). The regional variability of pTPP tau suggests that examining different phosphorylation sites is essential for a comprehensive assessment of tau pathology.
ALZHEIMERS & DEMENTIA
(2023)
Article
Chemistry, Physical
Sepideh Najar-Ahmadi, Hossein Haghaei, Safar Farajnia, Reza Yekta, Jafar Ezzati Nazhad Dolatabadi, Mohammad-Reza Rashidi
Summary: Alzheimer's disease is characterized by the accumulation of beta amyloid fibrils and phosphorylated tau in neurofibrillary tangles. Research suggests that donepezil may interact with tau protein, enhancing its binding to the protein with the main forces involved being van der Waals and hydrogen bonding. Molecular modeling analysis shows that donepezil binds to a cavity on the R2 region-microtubule binding domain of tau monomer.
JOURNAL OF MOLECULAR LIQUIDS
(2021)
Article
Neurosciences
Shu-Yu Liang, Zuo-Teng Wang, Lan Tan, Jin-Tai Yu
Summary: This article introduces the function and dysfunction of microtubule-associated protein tau in the central nervous system and discusses its role in neurodegenerative diseases, tau phosphorylation-related enzymes and proteins, and its relationship with cell dysfunction. The study of tau neurotoxicity provides new directions for the treatment of tauopathies.
MOLECULAR NEUROBIOLOGY
(2022)
Article
Immunology
Jiahui Zhu, Xingjun Jiang, Yanmin Chang, Yanqing Wu, Shangqi Sun, Cailin Wang, Siyi Zheng, Min Wang, Yi Yao, Gang Li, Rong Ma
Summary: The study found that clemastine fumarate shows potential in treating Alzheimer's disease. It reduces Tau protein deposition, protects neurons and synapses, reduces neuroinflammation, and improves cognitive function.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Jakub Sinsky, Karoline Pichlerova, Jozef Hanes
Summary: Tau protein is crucial for the normal function of neurons and the brain by regulating microtubules, but in diseased conditions, pathological modifications can lead to aggregation and formation of harmful structures like PHFs and NFTs, causing neuronal loss and death.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Luca Pinzi, Nicolo Bisi, Claudia Sorbi, Silvia Franchini, Nicolo Tonali, Giulio Rastelli
Summary: Tau is a protein with large structural portions that undergo extended conformational changes. Accumulation of Tau protein into toxic aggregates in neuronal cells leads to severe tauopathies. Recent research advancements have provided a better understanding of Tau structures and their implications in different tauopathies. This review presents an up-to-date overview of Tau structures reported in the Protein Data Bank, focusing on the connections between structural features, tauopathies, crystallization conditions, and sample types. The information presented highlights interesting links that could aid in the design of compounds to modulate Tau aggregation.
Article
Biochemistry & Molecular Biology
Narendran Annadurai, Jiri Hruby, Agata Kubickova, Lukas Malina, Marian Hajduch, Viswanath Das
Summary: Tauopathies are neurodegenerative diseases categorized into three types based on tau isoforms. Differences in seeding propensities and induction of tau aggregation were observed between R2 and R3 aggregates. The accumulation of pSer262 tau was visible earlier in cells induced with R2 aggregates, suggesting a role for the R2 region in disease progression and neuropathology of 4R tauopathies.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Biochemistry & Molecular Biology
Ying-Ying Gao, Tao Zhong, Li-Qiang Wang, Na Zhang, Yan Zeng, Ji-Ying Hu, Hai-Bin Dang, Jie Chen, Yi Liang
Summary: Zinc promotes liquid-liquid phase separation and aggregation of full-length Tau, resulting in the formation of stress granules and interaction with G3BP1, leading to increased Tau filaments and neuronal toxicity. Additionally, zinc aggravates mitochondrial damage and reactive oxygen species production induced by Tau aggregation, further deteriorating the pathogenesis of Alzheimer's disease.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Article
Chemistry, Applied
Weihua Jin, Chenghui Lu, Yanan Zhu, Jing Zhao, Wenjing Zhang, Lianchun Wang, Robert J. Linhardt, Chunyu Wang, Fuming Zhang
Summary: Tau spreading in Alzheimer's disease is mediated by cell surface heparan sulfate (HS). Fucoidans, a class of sulfated polysaccharides, can compete with HS to bind tau and inhibit tau spreading. Two fractions of fucoidans, sulfated galactofucan (SJ-I) and sulfated heteropolysaccharide (SJ-GX-3), exhibited strong binding abilities and inhibited tau-cell interaction and tau cellular uptake.
CARBOHYDRATE POLYMERS
(2023)
Review
Biochemistry & Molecular Biology
Zdenek Fisar
Summary: Damage or loss of brain cells and impaired neurochemistry, neurogenesis, and synaptic and nonsynaptic plasticity of the brain lead to dementia in neurodegenerative diseases, such as Alzheimer's disease (AD). Injury to synapses and neurons and accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles are considered the main morphological and neuropathological features of AD. Age, genetic and epigenetic factors, environmental stressors, and lifestyle contribute to the risk of AD onset and progression. These risk factors are associated with structural and functional changes in the brain, leading to cognitive decline. Biomarkers of AD reflect or cause specific changes in brain function, especially changes in pathways associated with neurotransmission, neuroinflammation, bioenergetics, apoptosis, and oxidative and nitrosative stress. Even in the initial stages, AD is associated with A beta neurotoxicity, mitochondrial dysfunction, and tau neurotoxicity. The integrative amyloid-tau-mitochondrial hypothesis assumes that the primary cause of AD is the neurotoxicity of A beta oligomers and tau oligomers, mitochondrial dysfunction, and their mutual synergy. For the development of new efficient AD drugs, targeting the elimination of neurotoxicity, mutual potentiation of effects, and unwanted protein interactions of risk factors and biomarkers (mainly A beta oligomers, tau oligomers, and mitochondrial dysfunction) in the early stage of the disease seems promising.
Review
Pharmacology & Pharmacy
Arunkumar Subramanian, T. Tamilanban, Abdulrhman Alsayari, Gobinath Ramachawolran, Ling Shing Wong, Mahendran Sekar, Siew Hua Gan, Vetriselvan Subramaniyan, Suresh V. V. Chinni, Nur Najihah Izzati Mat Rani, Nagaraja Suryadevara, Shadma Wahab
Summary: The primary and significant weakening event in elderly individuals is age-dependent cognitive decline and dementia, with Alzheimer's disease being the chief cause. Understanding the molecular mechanisms underlying Alzheimer's disease and other cognitive deficits is crucial. The regulatory relationship between the mammalian target of rapamycin (mTOR) signaling pathway and Alzheimer's disease, as well as the role of autophagy, is pivotal. Exploring the link between mTOR and autophagy further holds potential for Alzheimer's disease therapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cell Biology
Soha Alali, Gholamhossein Riazi, Mohammad Reza Ashrafi-Kooshk, Sogol Meknatkhah, Shahin Ahmadian, Mohammad Hooshyari Ardakani, Baharak Hosseinkhani
Summary: A hallmark of Alzheimer's disease is the accumulation of tau protein in the brain. CBD may serve as a potent substance to hinder tau aggregation in AD. Studies using biochemical methods have shown that CBD can suppress tau fibrils formation.
Article
Chemistry, Multidisciplinary
Linlin Xu, Yuxun Ding, Feihe Ma, Yue Chen, Guidong Chen, Lin Zhu, Jiafu Long, Rujiang Ma, Yang Liu, Jianfeng Liu, Fan Huang, Linqi Shi
Summary: Researchers have developed a customized nanochaperone protein for targeting intracellular pathological tau in Alzheimer's disease. This protein effectively inhibits tau aggregation and improves cognitive deficits. The nanochaperone exhibits selectivity and does not interfere with normal tau function. This study provides valuable insights for the treatment of Alzheimer's disease and other neurodegenerative disorders.
Review
Biochemistry & Molecular Biology
Andrea Gonzalez, Sandeep Kumar Singh, Macarena Churruca, Ricardo B. Maccioni
Summary: Alzheimer's disease is a neurodegenerative disease characterized by progressive cognitive impairment, apathy, and neuropsychiatric disorders. The main pathological features are tau oligomers and Aβ plaques. Protein kinases and phosphatases play a role in the hyperphosphorylation of tau and its self-assembly.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Francesca Munari, Luca Mollica, Carlo Valente, Francesca Parolini, Elham Ataie Kachoie, Giorgio Arrigoni, Mariapina D'Onofrio, Stefano Capaldi, Michael Assfalg
Summary: The study reveals that E3 ligase CHIP can ubiquitinate Tau protein at multiple sites, even in the absence of molecular chaperones, providing mechanistic insight into the chaperone-independent engagement of a disordered protein by its E3 ligase.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2022)
Review
Transplantation
Katryna Cisek, Magdalena Krochmal, Julie Klein, Harald Mischak
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2016)
Article
Gastroenterology & Hepatology
Burkhardt Flemer, Ryan D. Warren, Maurice P. Barrett, Katryna Cisek, Anubhav Das, Ian B. Jeffery, Eimear Hurley, Micheal O'Riordain, Fergus Shanahan, Paul W. O'Toole
Article
Multidisciplinary Sciences
Raquel M. Melero-Fernandez de Mera, Li-Li Li, Arkadiusz Popinigis, Katryna Cisek, Minna Tuittila, Leena Yadav, Andrius Serva, Michael J. Courtney
NATURE COMMUNICATIONS
(2017)
Article
Multidisciplinary Sciences
Magdalena Krochmal, Katryna Cisek, Szymon Filip, Katerina Markoska, Clare Orange, Jerome Zoidakis, Chara Gakiopoulou, Goce Spasovski, Harald Mischak, Christian Delles, Antonia Vlahou, Joachim Jankowski
SCIENTIFIC REPORTS
(2017)
Article
Neurosciences
Li-Li Li, Katryna Cisek, Michael J. Courtney
FRONTIERS IN MOLECULAR NEUROSCIENCE
(2017)
Article
Biochemistry & Molecular Biology
Katryna Cisek, Jeff Kuret
BIOORGANIC & MEDICINAL CHEMISTRY
(2012)
Article
Biochemistry & Molecular Biology
Katryna Cisek, Jordan R. Jensen, Nicolette S. Honson, Kelsey N. Schafer, Grace L. Cooper, Jeff Kuret
BIOPHYSICAL CHEMISTRY
(2012)
Article
Clinical Neurology
Katryna Cisek, Grace L. Cooper, Carol J. Huseby, Jeff Kuret
CURRENT ALZHEIMER RESEARCH
(2014)
Article
Neurosciences
Jordan R. Jensen, Katryna Cisek, Kristen E. Funk, Swati Naphade, Kelsey N. Schafer, Jeff Kuret
JOURNAL OF ALZHEIMERS DISEASE
(2011)
Article
Biochemistry & Molecular Biology
Kelsey N. Schafer, Katryna Cisek, Carol J. Huseby, Edward Chang, Jeff Kuret
JOURNAL OF BIOLOGICAL CHEMISTRY
(2013)
Article
Gastroenterology & Hepatology
Ian B. Jeffery, Anubhav Das, Eileen O'Herlihy, Simone Coughlan, Katryna Cisek, Michael Moore, Fintan Bradley, Tom Carty, Meenakshi Pradhan, Chinmay Dwibedi, Fergus Shanahan, Paul W. O'Toole
Article
Clinical Neurology
Alejandro Garcia-Rudolph, Joan Sauri, Blanca Cegarra, Vince Istvan Madai, Dietmar Frey, John D. Kelleher, Katryna Cisek, Eloy Opisso, Josep Maria Tormos, Montserrat Bernabeu
Summary: This study identifies three distinct classes of stroke patients based on their motor functional independence trajectories. These classes are characterized by different baseline clinical features and provide valuable insights into predicting long-term functional outcomes after stroke.
NEUROREHABILITATION
(2022)
Article
Clinical Neurology
Helard Becerra Martinez, Katryna Cisek, Alejandro Garcia-Rudolph, John D. Kelleher, Andrew Hines
Summary: Accurate early predictions of cognitive improvement in stroke rehabilitation are important for clinicians to develop effective therapeutic programs. This study presents a machine learning model that predicts cognitive improvement after therapy for stroke surviving patients and identifies influential factors for the prediction, providing guidance for adjusting therapeutic settings.
FRONTIERS IN NEUROLOGY
(2022)
Review
Urology & Nephrology
Theofilos Papadopoulos, Magdalena Krochmal, Katryna Cisek, Marco Fernandes, Holger Husi, Robert Stevens, Jean-Loup Bascands, Joost P. Schanstra, Julie Klein
CLINICAL KIDNEY JOURNAL
(2016)